Scientists are discovering that the human body is not genetically identical from one cell to the next. The phenomenon, known as somatic mosaicism, is reshaping how researchers think about ageing, disease and genetic testing.
Your body began with a single fertilised egg. That cell divided, its descendants divided again, and over time an extraordinary number of cells formed the tissues and organs that make you who you are.
It is tempting to imagine that every one of those cells carries exactly the same DNA. After all, the genetic blueprint inherited at conception is copied again and again throughout development.
But biology is rarely that tidy.
As cells divide, small changes can arise in their DNA. Some mutations occur during ordinary cell replication; others follow exposure to damaging agents or emerge through imperfect DNA repair. Most have little noticeable effect. Some remain confined to a handful of cells, while others spread through a much larger patch of tissue as those cells multiply.
The result is a body containing populations of cells with slightly different genetic makeups. Scientists call this somatic mosaicism.
It is not a rare anomaly limited to people with unusual genetic disorders. Researchers increasingly recognise that genetic differences between cells are a normal consequence of development and ageing. In certain circumstances, however, those differences can help explain disease, influence how a condition appears, or complicate the interpretation of a genetic test.
The discovery is changing a basic assumption in genetics: the DNA found in one sample may not tell the entire story of what is happening throughout a person’s body.
What is somatic mosaicism?
The word mosaic is useful because it evokes a surface assembled from different pieces. In the body, those pieces are groups of cells carrying genetic changes that are absent from other cells.
Imagine a mutation occurring in a cell during early embryonic development. That cell continues dividing, passing the change to its descendants. Depending on when the mutation occurs and which developmental branch the affected cell belongs to, the resulting group may contribute to a particular organ, several tissues or a substantial portion of the body.
A mutation that occurs much later may affect only a small cluster of cells in one tissue.
This timing can make a profound difference. An early mutation has more opportunities to spread into multiple cell lineages. A late mutation is generally more restricted, although the final distribution also depends on the affected cell type and how its descendants behave.
According to MedlinePlus Genetics, mosaicism can affect blood cells, skin cells and reproductive cells, among others. Its consequences vary according to the genetic change, the number of affected cells and the tissues involved.
The concept is not new, but the ability to detect mosaicism has improved dramatically. Modern DNA sequencing can identify genetic variants present in a relatively small fraction of a sample, revealing patterns that older tests might have missed.
A major review in Annual Review of Physiology explains how these discoveries have expanded understanding of mosaicism in development, ageing and disease. The review, “Somatic Mosaicism in Biology and Disease”, describes how genetically distinct cell populations can emerge and how researchers are investigating their effects.
The important point is that a genetic difference within the body is not automatically a disease. Its significance depends on what changed, where it changed and what the affected cells do.
Your cells acquire mutations throughout life
DNA is copied with remarkable accuracy, but not perfectly. Every time a cell divides, its genetic material must be replicated. Repair systems correct many mistakes, yet some changes escape detection and become permanent mutations.
Cells can also accumulate DNA damage from normal metabolic processes, ultraviolet radiation and other environmental exposures. If damage is repaired incorrectly—or not repaired before DNA is copied—it can leave a lasting genetic change.
These mutations do not all have the same consequences.
A change in a stretch of DNA that has little effect on cellular function may remain biologically inconsequential. Another mutation might interfere with a gene needed for normal growth. Occasionally, a mutation gives a cell a competitive advantage, allowing it to divide more successfully than its neighbours.
That last possibility is especially important.
When a mutated cell produces a growing population of descendants, researchers call the expansion a clone. The process is known as clonal expansion. It can occur in tissues that appear normal under a microscope, not only in tumours.
Scientists have found evidence of expanding mutant cell populations in skin, the oesophagus and blood. A landmark study published in Science in 2015 found that normal human skin can contain numerous cell clones carrying mutations associated with cancer. The presence of such mutations did not mean that every affected patch would become cancerous; it showed that mutations and selection can occur in apparently healthy tissue.
The research, “High burden and pervasive positive selection of somatic mutations in normal human skin”, helped demonstrate why genetic changes cannot be interpreted in isolation. A mutation’s effect depends partly on the environment in which the cell exists and whether the change helps that cell survive or multiply.
Ageing provides more time for these events to occur. Cells experience years of DNA damage, replication and repair, while tissue environments change. As a result, some kinds of somatic mosaicism become more common with age.
That does not mean the body inevitably becomes dysfunctional as mutations accumulate. Most mutations do not produce an obvious effect, and tissues have safeguards that limit the growth of abnormal cells. The scientific challenge is identifying which changes matter and why.
When different genetic histories influence disease
For many years, genetic testing was often explained through a simple model: a person carries a particular genetic variant, and that variant helps explain a disease or trait.
Mosaicism complicates that picture.
A disease-causing mutation may be present in only a proportion of a person’s cells. If it affects the cells responsible for a particular function, the consequences can depend on how widely the mutation is distributed and how much normal tissue remains.
Some genetic conditions are recognised in mosaic forms, including certain cases of neurofibromatosis and chromosomal conditions. People with mosaic forms can have different clinical features from people whose cells all carry the same relevant genetic alteration.
Consider a mutation affecting a gene involved in tissue development. If the change occurs very early, it may influence several organs. If it arises later, it may affect only a limited region. The resulting pattern can be highly variable, even when the underlying gene is the same.
Researchers also study mosaic mutations in cancer. Many tumours arise after a series of genetic and cellular changes, but some mutations can be detected in non-cancerous tissue long before a tumour develops. The presence of a mutation may indicate an altered cell population without proving that cancer will follow.
This distinction matters for patients. A genetic finding is not always a diagnosis, and the same variant can have different implications depending on the tissue tested, the proportion of cells carrying it and the person’s medical history.
The National Library of Medicine’s review of somatic mosaicism in the human genome describes how the timing, location and biological effects of mutations influence whether mosaicism causes disease.
Researchers are also investigating mosaicism in some neurological and developmental disorders. When a mutation occurs during brain development, it may be present in only a subset of cells. Such changes can be difficult to detect in a blood sample because the affected cells may be concentrated in the brain or another tissue.
That creates a practical problem: a negative result from one sample cannot always exclude a mosaic genetic change elsewhere in the body.
The surprising role of blood-cell mutations in ageing
Blood cells are continually replenished by haematopoietic stem cells, which live primarily in the bone marrow. As these stem cells divide and generate descendants, some acquire mutations. Most do not gain a major advantage, but certain mutations can help a cell line expand over time.
When a substantial population of blood cells descends from a stem cell carrying a particular mutation, the process is called clonal haematopoiesis.
It becomes more common with age. Researchers have identified mutations in genes such as DNMT3A, TET2 and ASXL1 in expanded blood-cell clones. Some of these genes are also associated with blood cancers, which is why the discovery can sound alarming.
But the distinction is crucial: clonal haematopoiesis does not mean a person has leukaemia, and most people with the finding will not develop a blood cancer.
The term clonal haematopoiesis of indeterminate potential, often shortened to CHIP, is used for a particular pattern of blood-cell mutations in people who do not have an established blood cancer or another qualifying blood disorder. The finding can be associated with an increased risk of future blood cancers and certain other health problems, but it is not a prediction that any one individual will become ill.
Scientists have also found associations between clonal haematopoiesis and cardiovascular disease. One proposed explanation is that some mutated immune cells may promote inflammatory processes that affect blood vessels. Laboratory studies have helped investigate possible mechanisms, although the precise clinical implications vary by mutation and individual circumstances.
A comprehensive review in Physiological Reviews explains the connection between clonal haematopoiesis, somatic mosaicism and age-associated disease. It is available through PubMed Central.
This research has opened a new window on ageing. Rather than viewing age-related disease only as the gradual deterioration of organs, scientists can also examine how cell populations evolve inside those organs over decades.
The field is still developing. Researchers are working to determine which mutations carry the greatest risks, how those risks change over time and whether interventions can safely reduce harmful effects. At present, a finding of clonal haematopoiesis should be interpreted by a qualified clinician in the context of the person’s blood counts, medical history and other risk factors—not treated as a standalone prediction.
Why genetic tests can miss mosaicism
Genetic tests do not examine every cell in the body. They analyse a sample, such as blood, saliva, skin or another tissue, and search for particular kinds of genetic changes.
That is usually useful, but mosaicism introduces two challenges.
The first is where the sample comes from. A mutation may be present in skin cells but absent from most blood cells, or it may be concentrated in a particular region of an organ. A blood test can therefore fail to detect a variant that exists elsewhere.
The second is how many cells carry the variant. If only a small fraction of the sampled cells contain a mutation, the signal may be too weak for some testing methods to identify reliably.
More sensitive sequencing techniques have improved detection, but the ability to find a variant depends on the test’s design, sequencing depth, technical limitations and the type of genetic change being investigated.
A laboratory may need to use a different method or analyse another tissue when mosaicism is suspected. In some cases, testing multiple tissues can help clarify the distribution of a variant. In others, the affected tissue may be difficult or inappropriate to sample.
This is particularly relevant when a person’s clinical features strongly suggest a genetic condition but a standard test does not find the expected variant.
The medical literature has highlighted these issues for years. A review in Clinical Genetics, “Detecting somatic mosaicism: considerations and clinical implications”, discusses the technical and clinical challenges involved in identifying mosaic variants.
For patients and families, the lesson is not that genetic testing is unreliable. It is that every test has a defined scope. A result answers a question about the sample and method used; it does not necessarily describe every cell in the body.
Only a clinician or genetic specialist can determine whether additional testing is appropriate in a particular case.
Not all genetic differences are inherited
Somatic mosaicism is also important because it differs from the genetic variation passed from parents to children.
Most inherited genetic variants are present in the fertilised egg and therefore, in principle, can be found throughout the body’s cell lineages. Somatic mutations arise after fertilisation and may be restricted to some tissues.
There is, however, an important complication: a genetic change can occur in reproductive cells as well as in ordinary body cells. This is called germline mosaicism when a proportion of a person’s egg or sperm cells carry a variant that may not be detectable in their blood or other sampled tissues.
That can help explain why parents with no obvious signs of a genetic condition may sometimes have more than one child affected by it. A variant may be present in some reproductive cells even though routine testing does not detect it in the parent’s blood.
The distinction matters for genetic counselling. Whether a mosaic variant can be passed to a child depends on which cell lineages carry it, including whether reproductive cells are involved. A somatic mutation confined to an ordinary body tissue generally will not be inherited by offspring.
There is no universal rule that can be applied to every case. The relevant gene, the nature of the variant and the tissues involved all matter. Families considering genetic testing or reproductive decisions should seek advice from a qualified genetics professional who can interpret the specific findings.
MedlinePlus provides an accessible overview of these distinctions in its explanation of gene variants and how they occur.
Could mosaicism help scientists understand ageing?
Ageing is not caused by a single process. It involves interacting changes in cells, tissues, metabolism, immunity and the body’s ability to maintain and repair itself.
Somatic mosaicism may be one part of that picture.
As people grow older, mutations accumulate in many tissues. Some cells continue to function normally despite carrying genetic changes. Others may become less effective, die, or gain an advantage that allows them to expand at the expense of neighbouring cells.
Researchers are investigating whether these processes contribute to age-related conditions beyond cancer, including cardiovascular and neurological disease. But it is important to distinguish an established observation from a proposed explanation.
The accumulation of somatic mutations with age is well documented. The contribution of particular mutations to a specific disease is more difficult to establish. A mutation may be a cause, a contributing factor or simply a marker of a cell population that has changed over time.
A review in Nature Reviews Genetics discusses how somatic mutations, clonal expansion and selection can influence health and disease. See “Mosaicism in health and disease — clones picking up speed”.
Newer technologies are allowing researchers to examine individual cells and compare genetic changes across tissues. These methods can reveal patterns that were previously invisible when scientists analysed a bulk sample containing millions of cells.
Over time, this work may improve understanding of how tissues change with age and why certain diseases develop in some people but not others. It may also help refine genetic testing, particularly when a mutation is present at a low level or restricted to a specific tissue.
What it will not necessarily provide is a simple genetic score that predicts how quickly a person will age. Human ageing is too complex for that conclusion to follow from mosaicism alone.
The limits of what scientists know
The growing evidence for somatic mosaicism has changed how researchers think about the genome, but major questions remain.
Scientists still need to establish the consequences of many mutations found in apparently healthy tissues. They must determine which changes are harmless, which influence cellular behaviour and which contribute meaningfully to disease.
They also need better ways to compare different tissues, identify low-frequency variants and follow cell populations over time. A mutation that is rare in one sample may be more common in another part of the body, while a genetic change that appears important in laboratory experiments may have little measurable effect in a person.
The same caution applies to possible treatments. Although understanding clonal haematopoiesis and other forms of mosaicism could eventually help clinicians identify risks or develop targeted therapies, research findings do not automatically translate into a treatment.
For now, somatic mosaicism is best understood as a fundamental feature of human biology with consequences that vary from one mutation and tissue to another.
One body, many genetic histories
The idea that every cell in the body carries an identical genetic blueprint is a useful starting point, but it is not the complete story.
From early development onward, cells acquire changes as they divide and respond to their environments. Some changes remain confined to small populations. Others spread through tissues, influence disease or become more common with age.
Modern sequencing is revealing this hidden diversity in far greater detail than was previously possible. It is helping researchers understand why genetic conditions can vary in severity, why a blood test may not tell the whole story and how some mutated cell populations expand in later life.
The discovery does not mean that a person’s identity is genetically fragmented, nor does it mean that every mutation is dangerous. Most genetic differences between cells do not produce an obvious health problem.
Instead, it reveals something more nuanced: the human body is a dynamic collection of living cell populations, each with its own history of replication, repair and occasional genetic change.
Understanding those histories may become an increasingly important part of medical genetics. For scientists, the challenge is no longer simply to ask which variants a person carries. It is to discover which cells carry them, how those cells behave and when those differences matter for health.
